Stock options take Takeda execs' pay past CEO
This article was originally published in Scrip
Yasuchika Hasegawa, the president and CEO of Asia's largest pharmaceutical company Takeda, was not surprisingly one of the highest paid pharma executives in Japan last year. But his earnings were overshadowed by three other senior executives within the company who all had total compensation packages worth more than double the chief executive's, with stock options accounting for most of the gap.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.